Compare Allegion PLC (ALLE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs Gilead Sciences, Inc. — how do they compare? Allegion PLC trades at $165.98 (market cap $14.32B), while Gilead Sciences, Inc. trades at $135.59 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 11.8× Allegion PLC's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| ALLE | GILD | |
|---|---|---|
Market Cap | $14.32B | $168.35B |
Sector | Industrials | Health |
52-Week High | $179.77 | $155.80 |
52-Week Low | $125.65 | $110.56 |
Enterprise Value | $16.03B | $191.42B |
Dividend Yield | 1.26% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $165.9, up 0.22% today, near its consensus price target of $156. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates, driven by 13% revenue growth and margin expansion in the Americas segment. Recent news highlights raised full-year guidance and institutional buying interest.
Outlook remains positive given earnings momentum and raised guidance, but risks include reliance on Americas growth and cost pressures. Analyst sentiment is mixed with a Hold consensus, yet the stock's current price above the target suggests limited near-term upside. Execution on international growth and margin sustainability are key for further appreciation.
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
